Comparative Pharmacology
Head-to-head clinical analysis: ALUPENT versus BRETHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUPENT versus BRETHINE.
ALUPENT vs BRETHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle, leading to bronchodilation.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Inhalation: 2 inhalations (0.65 mg per inhalation) every 3-4 hours, up to 12 inhalations per day. Oral: 20 mg three to four times daily.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
None Documented
None Documented
The terminal elimination half-life of metaproterenol (Alupent) is approximately 2.5–5 hours after oral administration, and 2–4 hours after intravenous or inhaled routes. Its relatively short half-life supports dosing every 4–6 hours for bronchodilator effect.
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Renal excretion of unchanged drug and metabolites accounts for approximately 40-60% of the dose, with the remainder eliminated via biliary/fecal routes. Following oral administration, about 30-40% is recovered in urine as unchanged drug and glucuronide conjugates, and 50-60% in feces. After intravenous administration, renal elimination is 40-50% unchanged, with biliary excretion contributing 30-40%.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist